KyungDong Pharm home
Prescription Medicines

Telodin Tab.

Product Category
overactive bladder medication
Active Ingredients
Tolterodine-L-tartrate
Appearance
A white, biconvex, round, film-coated tablet.
Reimbursement Code
648102140
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Tolterodine-L-tartrate (in-house specification)----2mg
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, silicon dioxide, calcium monohydrogen phosphate dihydrate, sodium starch glycolate, polyethylene glycol 6000, hypromellose 2910

2. Effectiveness
Treatment of overactive bladder for symptoms such as urinary urgency, frequency, or urge incontinence

3. Dosage and dosage
Adults: Tolterodine-L-tartrate, 2 mg orally twice a day.
However, based on the patient's response and tolerance to the drug, the single dose can be reduced from 2 mg to 1 mg and administered twice a day.
Patients with renal dysfunction, hepatic dysfunction, or patients taking ketoconazole or other strong CYP3A4 inhibitors: 1 mg twice daily is recommended.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with symptoms of urinary retention
2) Patients with symptoms of gastric stasis
3) Patients with uncontrolled narrow-angle glaucoma
4) Patients with hypersensitivity to this drug or its components
5) Patients with myasthenia gravis
6) Patients with severe ulcerative colitis
7) Patients with toxic megacolon

2. Administer with caution to the following patients.
1) Patients with significant bladder outlet obstruction at risk of urinary retention
2) Patients with accommodative narrow-angle glaucoma
3) Patients with gastrointestinal obstructive diseases such as pyloric stenosis
4) Patients with renal dysfunction
5) Patients with liver dysfunction
6) Patients taking other strong CYP3A4 inhibitors such as macrolide antibiotics (erythromycin, clarithromycin, etc.), azole antifungals (ketoconazole, itraconazole, miconazole, etc.), cyclosporine, or vinblastine.
7) Patients with autonomic neuropathy
8) Hiatal hernia patient
9) Patients at risk of decreased gastrointestinal motility

3. Adverse reactions
1) This drug may cause mild to moderate antimuscarinic effects such as dry mouth, indigestion, and decreased tearing.
2) The following are adverse reactions reported in clinical trials and believed to have a causal relationship with this drug.
(1) Infection: Bronchitis
(2) Immune system: allergic reaction
(3) Mental nervous system: confusion, drowsiness, dizziness, headache, nervousness, anxiety, paresthesia
(4) Digestive system: Dry mouth, indigestion, constipation, abdominal pain, flatulence in the intestines, vomiting, gastroesophageal reflux.
(5) Urinary system: urinary retention, dysuria, dysuria
(6) Whole body: chest pain, weight gain, fatigue
(7) Eyes and ears: dry eyes, visual abnormalities (including vision control disorders), dizziness
(8) Vascular system: skin flushing
(9) Skin and subcutaneous tissue: skin dryness
3) Regardless of the causal relationship with this drug, adverse reactions reported after administration of this drug are as follows.
(1) Immune system: infection
(2) Digestive system: Diarrhea
(3) Mental nervous system: drowsiness
(4) Respiratory system: Sinusitis
(5) Whole body: joint pain
4) Adverse reactions reported in post-marketing use experience in each country are as follows.
(1) Immune system: Anaphylactic reaction
(2) Mental system: hallucinations, disorientation, memory impairment
(3) Heart: tachycardia, palpitations
(4) Digestive system: Diarrhea
(5) Skin and subcutaneous tissue: angioedema
(6) Whole body and administration site: peripheral edema
(7) In patients taking cholinesterase inhibitors for the treatment of dementia, worsening of dementia symptoms (e.g., confusion, disorientation, delusions) has been reported after starting treatment with this drug.
5) Domestic post-marketing survey results
As a result of a post-marketing use outcome survey conducted on 8,090 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 8.27% (669 cases/8,090 cases) regardless of causal relationship, and among these, 7.99% (646 cases/8,090 cases) were found to have a causal relationship with this drug.
Adverse reactions that have been found to have a causal relationship with this drug (or for which a causal relationship cannot be ruled out) are listed by frequency of occurrence as follows.
Dry mouth was the most common at 5.43% (439 cases/8,090 cases), constipation at 0.88% (71 cases/8,090 cases), dyspepsia at 0.87% (70 cases/8,090 cases), urinary retention at 0.67% (54 cases/8,090 cases), and headache at 0.25% (20 cases/8,090 cases). Appeared in order. Abdominal pain, drowsiness, and dry eyes were reported in 0.1% each, and in less than 0.1%, nervousness, vomiting, difficulty urinating, edema, visual abnormalities (visual disturbance, etc.), diarrhea, dizziness, fatigue, stomach ulcer, abdominal distension, facial edema, paresthesia, insomnia, confusion, facial flushing, dry skin, duodenal ulcer, apathy, asthenia, itching, hypersensitivity to the skin, γ-GTP abnormalities have been reported. Among these, adverse reactions newly reported in the post-marketing use results survey included 3 cases of diarrhea, 2 cases each of insomnia, gastric ulcer, facial edema, and facial flushing, and 1 case each of edema, duodenal ulcer, apathy, asthenia, itching, skin sensitivity, and γ-GTP abnormality.

4. General precautions
1) As a result of studying the effect of this drug on the QT interval, it was found that the effect was greater when administered at 8 mg per day (twice the therapeutic dose) than when administered at 4 mg per day, and the effect on the QT interval was more evident in people with reduced metabolic ability than in people with extensive metabolism of CYP2D6. This should be taken into consideration when administering this drug to the following patients:
(1) Patients with congenital or acquired QT prolongation
(2) Patients taking drugs known to prolong the QT interval, including class IA (quinidine, procainamide, etc.) or class III (amiodarone, sotalol, etc.) antiarrhythmic drugs
(3) Electrolyte abnormalities such as hypokalemia, hypomagnesemia, and hypocalcemia
(4) bradycardia
(5) In particular, caution should be exercised when administering a strong CYP3A4 inhibitor, and concomitant treatment with a strong CYP3A4 inhibitor should be avoided.
2) This drug may cause coordination problems and affect reaction times, which may negatively affect the ability to drive and operate machinery.
3) Before treatment, structural causes of urinary urgency and frequency should be considered along with all treatment methods for unstable bladder.
5. Interaction
1) When administered concurrently with other antimuscarinic drugs such as antidepressants, the antimuscarinic effect may be increased. Conversely, the therapeutic effect of this drug may be reduced by concomitant administration of muscarinic cholinergic receptor agonists.
2) Pharmacokinetic interactions may occur when used together with other drugs that are metabolized by or inhibit CYP2D6. However, co-administration with fluoxetine, a strong CYP2D6 inhibitor, does not cause clinically significant interactions. This is because this drug and its CYP2D6-dependent metabolite, 5-hydroxymethyltolterodine, have the same action.
3) When this drug was coadministered with ketoconazole, a strong CYP3A4 inhibitor, in people with reduced metabolic capacity (such as those lacking the CYP2D6 metabolic pathway), the plasma concentration of this drug significantly increased.
4) In clinical trials, no interaction with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel) was observed.
5) The effectiveness of prokinetics such as metoclopramide and cisapride may be reduced by this drug.
6) In clinical studies, this drug did not inhibit the metabolism of CYP2D6, 2C9, 2C19, 3A4, or 1A2. Therefore, an increase in the plasma concentration of drugs metabolized by the isoenzyme system is not expected when co-administered with this drug.

6. Administration to pregnant and lactating women
1) There is no clinical experience in treating pregnant women. Studies in pregnant mice have shown that high doses cause decreased fetal weight, embryonic lethality, and increased rates of fetal malformations. This medication should not be given to pregnant women until more information is available.
Women of childbearing potential should only be considered for administration if they are using adequate contraception.
2) In mice, this drug is secreted into milk. As there are no data on its transfer into breast milk in humans, this medication should not be used during lactation.

7. Administration to children
Safety and efficacy in children have not been established.

8. Treatment in case of overdose
1) The highest dose of this drug administered to healthy volunteers is 12.8 mg as a single dose. The most serious adverse reactions observed were impaired vision control and dysuria.
2) In case of overdose of this drug, standard supportive care should be administered to treat QT prolongation. Gastric lavage should be performed, medicinal charcoal should be administered, and symptoms should be treated as follows.
(1) If severe central antimuscarinic effects (e.g. hallucinations, severe excitement) are significant, physostigmine is administered.
(2) If significant excitement or convulsions occur, benzodiazepine drugs may be administered.
(3) In case of respiratory failure, perform artificial respiration.
(4) Tachycardia can be treated with beta blockers.
(5) Urinary retention is treated with catheterization.
(6) If intractable pupil dilation occurs, consider administering pilocarpine eye drops while keeping the patient in a dark room.
9. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Airtight container, stored at room temperature below 25℃

6. Packaging unit
30 tablets (10 tablets/PTP x 3)

7. Expiration date
24 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Telodin Tab.Telodine tablets (efficacy, dosage, directions for use...2013.12.30HWP2012 Pharmaceutical Literature Re-evaluation (Telodine Tablets).hwp
2Telodin Tab.Telodine tablets (precautions for use)2008.08.06HWPChange in Telodine tablets (precautions for use) (2008.08.08).hwp
1Telodin Tab.Telodine tablets (precautions for use)2007.11.21HWPChange in Telodine tablets (precautions for use) (2007.11.26).hwp